Codexis Inc (OQ:CDXS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 200 Penobscot Dr
REDWOOD CITY CA 94063-4718
Tel: 1-650-4218399
Website: https://www.codexis.com
IR: See website
<
Key People
Stephen G. Dilly
President, Chief Executive Officer, Director
Sriram Ryali
Chief Financial Officer, Chief Accounting Officer
Kevin Norrett
Chief Operating Officer
Margaret Nell Fitzgerald
Chief Legal and Compliance Officer, General Counsel and Secretary
   
Business Overview
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Financial Overview
For the fiscal year ended 31 December 2023, Codexis Inc revenues decreased 49% to $70.1M. Net loss increased from $33.6M to $76.2M. Revenues reflect EMEA segment decrease of 59% to $22.9M, APAC segment decrease of 48% to $33.5M. Higher net loss reflects Other expenses net, decrease from $124K (income) to $12.3M (expense), Selling and General Expenses increase of 10% to $46M (expense).
Employees: 174 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $180.24M as of Dec 31, 2023
Annual revenue (TTM): $70.14M as of Dec 31, 2023
EBITDA (TTM): -$49.28M as of Dec 31, 2023
Net annual income (TTM): -$76.24M as of Dec 31, 2023
Free cash flow (TTM): -$57.06M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 70,303,639 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.